Kiora Pharmaceuticals, Inc.
KPRX
$2.10
$0.2111.11%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 18.46% | 59.88% | |||
| Gross Profit | -18.46% | -59.88% | |||
| SG&A Expenses | 6.64% | -9.10% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.38% | 9.89% | |||
| Operating Income | -11.38% | -9.89% | |||
| Income Before Tax | 72.78% | -9.40% | |||
| Income Tax Expenses | -473.68% | -191.14% | |||
| Earnings from Continuing Operations | 101.25% | 1.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 101.25% | 1.85% | |||
| EBIT | -11.38% | -9.89% | |||
| EBITDA | -11.08% | -9.74% | |||
| EPS Basic | 101.15% | -3.77% | |||
| Normalized Basic EPS | -2.19% | -25.26% | |||
| EPS Diluted | 101.15% | -3.85% | |||
| Normalized Diluted EPS | -0.51% | -25.26% | |||
| Average Basic Shares Outstanding | 7.54% | -5.41% | |||
| Average Diluted Shares Outstanding | 9.34% | -5.41% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||